-
Model Transparency and Validation: Report 7
-
Content Validity - Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation Part 1
-
Content Validity – Establishing and Reporting the Evidence in Newly Developed Patient-Reported Outcomes (PRO) Instruments for Medical Product Evaluation Part 2
-
Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making Report 1
-
Conducting Indirect Treatment Comparison and Network Meta-Analysis Studies Report 2
-
Conjoint Analysis Applications in Health - A Checklist
-
Quantitative Risk–Benefit Methodologies for Assessing Drug Safety and Efficacy - Report of ISPOR Risk–Benefit Management Working Group
-
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations - ISPOR drug cost task force report - Part I
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective - ISPOR drug cost task force report - Part II
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Managed Care Perspective - ISPOR drug cost task force report - Part III
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: Medicare, Medicaid and US Government Payers Perspectives ISPOR drug cost task force report - Part IV
-
Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: An Industry Perspective - ISPOR drug cost task force report - Part V
-
Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: An International Perspective - ISPOR drug cost task force report - Part VI
-
Costs of Medication Non adherence in Patients with Diabetes Mellitus: A Systematic Review and Critical Analysis of the Literature
-
Use of Existing Patient-Reported Outcome (PRO) Instruments and Their Modification
-
The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report
-
Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources - Task Force Report Part III
-
Good research practices for comparative effectiveness research - bias & confounding in the design - Task Force Report Part II
-
Good research practices for comparative effectiveness research – defining, reporting & interpreting - Task Force Report Part I
-
Multinational Trials – Recommendations on the Translations Required, Approaches to Using the Same Language in Different Countries, and the Approaches to Support Pooling the Data
Questions?
For any questions about this report please contact us.